Research programme: antibody directed enzyme prodrug therapy - Genencor

Drug Profile

Research programme: antibody directed enzyme prodrug therapy - Genencor

Alternative Names: GCR-8886/2141

Latest Information Update: 14 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genencor International
  • Class Amidohydrolases; Antibodies; Recombinant fusion proteins
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 13 Jun 2005 Genencor International has been acquired by Danisco A/S
  • 23 Mar 2005 Genencor has filed an IND with the FDA in USA for colorectal and pancreatic cancer
  • 07 Dec 2004 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top